Immunotherapy for renal cell carcinoma

Katsunori Tatsugami, Momoe Itsumi

研究成果: ジャーナルへの寄稿評論記事

38 引用 (Scopus)

抄録

Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

元の言語英語
記事番号284581
ジャーナルClinical and Developmental Immunology
2010
DOI
出版物ステータス出版済み - 12 1 2010

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Regulatory T-Lymphocytes
Clinical Trials
Antigen-Presenting Cells
Dendritic Cells
Radiotherapy
Cytokines
Safety
Antigens
Drug Therapy
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

Immunotherapy for renal cell carcinoma. / Tatsugami, Katsunori; Itsumi, Momoe.

:: Clinical and Developmental Immunology, 巻 2010, 284581, 01.12.2010.

研究成果: ジャーナルへの寄稿評論記事

@article{6d7932d91387455dbbdf44c1e4aa616a,
title = "Immunotherapy for renal cell carcinoma",
abstract = "Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.",
author = "Katsunori Tatsugami and Momoe Itsumi",
year = "2010",
month = "12",
day = "1",
doi = "10.1155/2010/284581",
language = "English",
volume = "2010",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Immunotherapy for renal cell carcinoma

AU - Tatsugami, Katsunori

AU - Itsumi, Momoe

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

AB - Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

UR - http://www.scopus.com/inward/record.url?scp=79952207249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952207249&partnerID=8YFLogxK

U2 - 10.1155/2010/284581

DO - 10.1155/2010/284581

M3 - Review article

VL - 2010

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 284581

ER -